Penumbra Inc(PEN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 78.04 | EPS (ttm) | 4.07 | Insider Own | 2.91% | Shs Outstand | 39.4M | Perf Week | -1.56% |
| Market Cap | 12.52B | Forward P/E | 53.06 | EPS next Y | 27.22% | Insider Trans | -0.01% | Shs Float | 38.2M | Perf Month | -2.61% |
| Enterprise Value | 12.07B | PEG | 2.4 | EPS next Q | 1.2 | Inst Own | 87.28% | Short Float | 4.76% | Perf Quarter | -0.49% |
| Income | 0.16B | P/S | 8.32 | EPS this Y | 22.6% | Inst Trans | 1.01% | Short Ratio | 5.3 | Perf Half Y | -5.45% |
| Sales | 1.50B | P/B | 8.18 | EPS next 5Y | 22.07% | ROA | 8.8% | Short Interest | 1.82M | Perf YTD | 2.21% |
| Book/sh | 38.86 | P/C | 19 | EPS past 3/5Y | - | ROE | 11.37% | 52W High | -12.31% ($362.41) | Perf Year | 16.84% |
| Cash/sh | 16.73 | P/FCF | 57.97 | Sales past 3/5Y | 18.33% 20.16% | ROIC | 9.3% | 52W Low | 43.62% ($221.26) | Perf 3Y | 8.46% |
| Dividend Est. | - | EV/EBITDA | 59.03 | EPS Y/Y TTM | 7.09% | Gross Margin | 66.72% | Volatility(W/M) | 0.72% 0.66% | Perf 5Y | 12.6% |
| Dividend TTM | - | EV/Sales | 8.02 | Sales Y/Y TTM | 17.55% | Oper. Margin | 12.45% | ATR (14) | 2.23 | Perf 10Y | 365.61% |
| Dividend Ex-Date | - | Quick Ratio | 3.86 | EPS Q/Q | -23.74% | Profit Margin | 10.67% | RSI (14) | 36.45 | Recom | 2.8 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.75 | Sales Q/Q | 14.9% | SMA20 | -1.67% ($323.18) | Beta | 0.7 | Target Price | $363.29 |
| Payout | - | Debt/Eq | 0.14 | Earnings | 2026/7/30 | SMA50 | -1.1% ($321.31) | Rel Volume | 0.4 | Prev Close | $319.57 |
| Employees | 4700 | LT Debt/Eq | 0.13 | EPS/Sales Surpr. | -24.3% 0.1% | SMA200 | -2.25% ($325.09) | Avg Volume(3M) | 0.34M | Price | $317.78 |
| IPO | 2015/9/18 | Option/Short | Yes/Yes | Trades | 4260 | Volume | 138,702 | Change | -0.56% |
Company
PEN is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A U.S. medical device company specializing in vascular interventional devices, focused on developing and supplying treatments for stroke and peripheral vascular disease, with thrombectomy devices that suction and remove blood clots from inside vessels as its core product.
Over the past 1 year, roughly in the middle
12% below its 1-year high.
PEN makes money exceptionally well
12.45% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +22.6% this year.
Tap to view numbers
But it is not cheap
Trading at 78.0 times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Long-term returns are close to the market
Would have changed by +8.5% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 87.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
RSBA 0.12%
TMFS 0.03%
CSMD 0.03%
ARB 0.03%
EVNT 0.03%Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
OPEX 7M
OPEG 1MIt ranks #4 in the industry
Based on market cap of $13B.
PEN $13B PER 78.0
ABT $179B PER 33.4
MDT $117B PER 22.6
SYK $104B PER 28.0
FAQ
What kind of company is PEN?
PEN belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of PEN?
The market cap of PEN is approximately $12.5B, ranking 811 within its sector.
What is the P/E ratio of PEN?
PEN has a P/E ratio of approximately 78.0x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for PEN?
PEN has recorded a 52-week high of $362.41 and a low of $221.26.
